Calithera Biosciences (CALA) Stock Price, News & Analysis

Company Overview

Calithera Biosciences, Inc. was a clinical-stage biopharmaceutical company focused on developing small-molecule therapies that target cancer metabolism. The company sought to exploit metabolic dependencies in tumor cells to create treatments for cancer, with research programs designed for use both as standalone therapies and in combination with existing medicines.

Calithera’s lead investigational product was telaglenastat (also known as CB-839), an oral inhibitor of glutaminase, an enzyme involved in glutamine metabolism. The drug was evaluated in clinical studies for several types of cancer, including renal cell carcinoma and triple-negative breast cancer. The company also pursued additional oncology programs involving other metabolic and immune-related targets.

Founded in 2010 and headquartered in South San Francisco, California, Calithera was led for much of its operating history by co-founder and former Chief Executive Officer Susan Molineaux. The company conducted development activities through clinical research and collaborations with pharmaceutical and biotechnology partners. After discontinuing key development programs and reducing operations, Calithera pursued a wind-down and bankruptcy proceedings, and it is no longer an active operating biotechnology company.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 5 shs
• Average Volume: 707 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/08/2021
• Today: 10/12/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CALA
• CIK: 1496671
• Web: www.calithera.com
• Phone: (650) 870-1000
• Fax: N/A
• Employees: 60
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,860,000
• Free Float: 4,550,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -1.52